• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.

作者信息

Soeiro Paula, Martins Helder, Silva Rodolfo, Moreira Ana Paula

机构信息

Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal

Nuclear Medicine, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.

出版信息

BMJ Case Rep. 2020 Mar 31;13(3):e233263. doi: 10.1136/bcr-2019-233263.

DOI:10.1136/bcr-2019-233263
PMID:32234855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7167446/
Abstract
摘要

相似文献

1
Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.肽受体放射性核素治疗3年后，不可切除的胰腺神经内分泌肿瘤肝转移和骨转移完全缓解。
BMJ Case Rep. 2020 Mar 31;13(3):e233263. doi: 10.1136/bcr-2019-233263.
2
Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.胰腺异位促肾上腺皮质激素分泌神经内分泌肿瘤经 177Lu-DOTATATE 诱导及维持肽受体放射性核素治疗。
Clin Nucl Med. 2016 Jan;41(1):50-2. doi: 10.1097/RLU.0000000000000971.
3
Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.对于伴有不可切除肝转移的G1-G2胰腺神经内分泌肿瘤，先行原发性肿瘤切除，随后进行肽受体放射性核素治疗作为一线治疗策略
Ann Surg Oncol. 2016 Dec;23(Suppl 5):981-989. doi: 10.1245/s10434-016-5550-3. Epub 2016 Sep 9.
4
Emerging treatment modalities for advanced pancreatic neuroendocrine tumors.晚期胰腺神经内分泌肿瘤的新兴治疗方式。
Hormones (Athens). 2016 Oct;15(4):563-564. doi: 10.14310/horm.2002.1702.
5
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.[Lu-DOTA,Tyr]奥曲肽挽救性肽受体放射性核素治疗支气管和胃肠胰腺神经内分泌肿瘤。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.
6
Additional hepatic Ho-radioembolization in patients with neuroendocrine tumours treated with Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).¹⁷⁷Lu-DOTATATE治疗的神经内分泌肿瘤患者的额外肝脏钬放射性栓塞；一项单中心、介入性、非随机、非对照、开放标签的II期研究（HEPAR PLUS试验）。
BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8.
7
Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.接受肽受体放射性核素治疗患者的心脏毒性
Pancreas. 2018 Sep;47(8):e55-e56. doi: 10.1097/MPA.0000000000001101.
8
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.用兰瑞肽预处理的转移性神经内分泌肿瘤患者使用长效醋酸奥曲肽
Ann Oncol. 2000 Sep;11(9):1127-30. doi: 10.1023/a:1008383132024.
9
Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with Lu-DOTATATE.胰腺神经内分泌肿瘤的巨大心脏转移及对镥[177Lu] DOTATATE肽受体放射性核素治疗的反应
J Nucl Cardiol. 2020 Feb;27(1):340-341. doi: 10.1007/s12350-018-1426-1. Epub 2018 Aug 27.
10
Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.小肠神经内分泌肿瘤的肝和骨转移对 177Lu-DOTATATE 诱导和维持治疗有反应。
Clin Nucl Med. 2015 Feb;40(2):162-5. doi: 10.1097/RLU.0000000000000569.

引用本文的文献

1
Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies.病例报告：伴门静脉血栓形成的转移性胰腺神经内分泌肿瘤；成功管理并随后妊娠。
Front Endocrinol (Lausanne). 2023 Feb 27;14:1095815. doi: 10.3389/fendo.2023.1095815. eCollection 2023.
2
Rare Bone Metastasis of Neuroendocrine Tumors of Unknown Origin: A Case Report and Literature Review.不明来源神经内分泌肿瘤罕见骨转移：病例报告及文献复习。
Orthop Surg. 2022 Oct;14(10):2766-2775. doi: 10.1111/os.13384. Epub 2022 Jul 20.

本文引用的文献

1
Molecular radionuclide imaging of pancreatic neoplasms.胰腺肿瘤的分子放射性核素显像。
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):559-570. doi: 10.1016/S2468-1253(19)30081-0.
2
Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.肽受体放射性核素治疗晚期胰腺神经内分泌肿瘤。
Semin Oncol. 2018 Aug;45(4):236-248. doi: 10.1053/j.seminoncol.2018.08.004. Epub 2018 Oct 24.
3
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.[Lu-DOTA,Tyr]奥曲肽挽救性肽受体放射性核素治疗支气管和胃肠胰腺神经内分泌肿瘤。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.
4
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.十二年肽受体放射性核素治疗随访。
J Nucl Med. 2019 Apr;60(4):524-529. doi: 10.2967/jnumed.118.215376. Epub 2018 Aug 16.
5
Prospective observational study of Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.200 例晚期转移性神经内分泌肿瘤（NETs）患者 Lu-DOTA-octreotate 治疗的前瞻性观察研究：剂量学指导研究方案对结果和毒性的影响。
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988. doi: 10.1007/s00259-018-3945-z. Epub 2018 Mar 1.
6
Carcinoid-syndrome: recent advances, current status and controversies.类癌综合征：最新进展、现状与争议
Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35. doi: 10.1097/MED.0000000000000376.
7
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
8
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.《欧洲神经内分泌肿瘤学会功能性胰腺神经内分泌肿瘤和非功能性胰腺神经内分泌肿瘤患者管理共识指南更新》
Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5.
9
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.国际原子能机构、欧洲核医学协会和核医学分子影像学会联合发布的神经内分泌肿瘤肽受体放射性核素治疗实践指南。
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.